Neil Kumar, Chief Executive Officer at BridgeBio Pharma, Inc. (BBIO), sold 159,280 shares at $61.14 ($9.9M) on 2025-11-07, disclosed to the SEC on 2025-11-10.
Scheduled sale ($9.9M) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $62.91 | 12,529 | $788K | 7.9% |
| 2 | $62.91 | 12,576 | $791K | 8.0% |
| 3 | $62.91 | 12,576 | $791K | 8.0% |
| 4 | $62.91 | 12,529 | $788K | 7.9% |
| 5 | $63.55 | 7,324 | $465K | 4.7% |
| 6 | $63.55 | 7,324 |
| $465K |
| 4.7% |
| 7 | $63.56 | 7,371 | $469K | 4.7% |
| 8 | $63.56 | 7,371 | $469K | 4.7% |
| 9 | $64.39 | 100 | $6K | 0.1% |
| 10 | $61.13 | 12,234 | $748K | 7.5% |
| 11 | $61.13 | 12,234 | $748K | 7.5% |
| 12 | $61.14 | 12,492 | $764K | 7.7% |
| 13 | $61.14 | 12,492 | $764K | 7.7% |
| 14 | $61.87 | 7,546 | $467K | 4.7% |
| 15 | $61.87 | 7,546 | $467K | 4.7% |
| 16 | $61.87 | 7,308 | $452K | 4.6% |
| 17 | $61.87 | 7,308 | $452K | 4.6% |
| 18 | $62.79 | 220 | $14K | 0.1% |
| 19 | $62.81 | 200 | $13K | 0.1% |
| Total | $62.28 avg | 159,280 | $9.9M | 100% |
| Filing → |
| BBIO | SELL | 2026-06-08 | $4.6M | — | Filing → |
| BBIO | SELL | 2026-05-26 | $1.8M | — | Filing → |
| BBIO | SELL | 2026-05-11 | $5.3M | — | Filing → |